OncoMyx Announces Presentations at IOVC 2021 on the Use of Multi-Armed Myxoma Virus as a Novel Oncolytic Immunotherapy

< back

PHOENIX, October 19, 2021 – OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, today announced four presentations at the upcoming 2021 International Oncolytic Virus Conference (IOVC) being held November 5-7, 2021, both virtually and in Sedona, Ariz. The company plans to present recent preclinical data demonstrating oncolytic activity, transgene production, immunomodulatory mechanisms of action, and efficacy of intratumoral (IT) and intravenous (IV) administration of OncoMyx’s multi-armed myxoma virotherapy for the treatment of cancer.

OncoMyx Talk and Poster Info

  • Session 1: Novel Payloads and Mechanisms of Action 1 with Leslie Sharp, PhD, CSO, will happen Friday, Nov. 5th from 8:55am – 9:20am MST
  • Poster Presentation (Virtual) with Lina Franco, PhD, Scientist II, is available on demand Friday, Nov. 5th – Sunday, Nov. 7th
  • A Special Session with Steve Potts, PhD, MBA, CEO and cofounder, entitled “Benefits of a systemic-delivered, multi-armed non-human pathogen, myxoma virus, against solid and heme cancers” will take place Saturday, Nov. 6th from 8:44pm – 8:56pm MST.
  • A Live Q&A for the poster presentation with Dr. Franco will be held Sunday, Nov. 7th from 1:00pm – 3:30pm MST.

The posters are available to view and download here (under publications).

About Oncolytic Immunotherapy and Myxoma Virus

Oncolytic viruses (OV) selectively replicate in and lyse tumor cells and provide stimulation to the immune system, representing a promising therapeutic option in development to treat cancers that do not respond well to treatment with immune checkpoint inhibitors. Myxoma virus (MYXV) is a member of the Pox family of double stranded DNA viruses. The natural host of MYXV is a subset of rabbits and hares, but MYXV is able to infect cancer cell lines of humans and other species. The genome of MYXV is relatively large and is amenable to engineering for expression of transgenic proteins, making it an excellent oncolytic virus for introduction of immunomodulatory proteins.

About OncoMyx Therapeutics

OncoMyx Therapeutics is advancing oncolytic immunotherapies with the goal of achieving the greatest therapeutic benefit for more cancer patients. Successful immuno-oncology cancer treatment generally requires combination therapy, and oncolytic viruses have the potential to be a safe and effective complement to immunotherapies. OncoMyx has assembled the top immuno-oncology team to develop oncolytic immunotherapies based on the myxoma virus platform to orchestrate an immune response with the goal of better treating a wide range of cancers. The company’s myxoma virus platform is poised to be a best-in-class oncolytic virus approach and was developed based on breakthrough research from Dr. Grant McFadden’s lab that was exclusively licensed from Arizona State University.

Corporate Contact: Michael G. Wood, Cofounder, COO, and CFO, mw@oncomyx.com

Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091